Seroatlas · Human Serome Atlas

HNRNPA2B1

Heterogeneous nuclear ribonucleoproteins A2/B1

Also known as: HNRPA2B1, ROA2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P22626
Gene
HNRNPA2B1
Ensembl
ENSG00000122566
Chromosome
7
Canonical length
353 aa
Protein class
Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins
Subcellular location
Nucleoplasm
Secretome location
Intracellular and membrane
Quaternary structure
Homodimer

OverviewNCBI Gene

This gene belongs to the A/B subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins (hnRNPs). The hnRNPs are RNA binding proteins and they complex with heterogeneous nuclear RNA (hnRNA). These proteins are associated with pre-mRNAs in the nucleus and appear to influence pre-mRNA processing and other aspects of mRNA metabolism and transport. While all of the hnRNPs are present in the nucleus, some seem to shuttle between the nucleus and the cytoplasm. The hnRNP proteins have distinct nucleic acid binding properties. The protein encoded by this gene has two repeats of quasi-RRM domains that bind to RNAs. This gene has been described to generate two alternatively spliced transcript variants which encode different isoforms. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

353 residues, UniProt reviewed canonical sequence.

>P22626|HNRNPA2B1
     1  MEKTLETVPL ERKKREKEQF RKLFIGGLSF ETTEESLRNY YEQWGKLTDC VVMRDPASKR
    61  SRGFGFVTFS SMAEVDAAMA ARPHSIDGRV VEPKRAVARE ESGKPGAHVT VKKLFVGGIK
   121  EDTEEHHLRD YFEEYGKIDT IEIITDRQSG KKRGFGFVTF DDHDPVDKIV LQKYHTINGH
   181  NAEVRKALSR QEMQEVQSSR SGRGGNFGFG DSRGGGGNFG PGPGSNFRGG SDGYGSGRGF
   241  GDGYNGYGGG PGGGNFGGSP GYGGGRGGYG GGGPGYGNQG GGYGGGYDNY GGGNYGSGNY
   301  NDFGNYNQQP SNYGPMKSGN FGGSRNMGGP YGGGNYGPGG SGGSGGYGGR SRY

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against HNRNPA2B1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.5
Highest tissue expression
172 nTPM

Expression across tissuesHPA

Tissue

  • lymph node: 172 nTPM
  • thymus: 163 nTPM
  • tonsil: 162 nTPM
  • skeletal muscle: 158 nTPM
  • spleen: 149 nTPM
  • ovary: 145 nTPM

Single-cell type

  • monocyte progenitors: 1,362 nCPM
  • syncytiotrophoblasts: 1,256 nCPM
  • cytotrophoblasts: 1,148 nCPM
  • megakaryocyte progenitors: 1,113 nCPM
  • extravillous trophoblasts: 1,107 nCPM
  • migrating cytotrophoblasts: 1,092 nCPM

Immune cell

  • gdT-cell: 4.8 nTPM
  • MAIT T-cell: 4 nTPM
  • NK-cell: 3.3 nTPM
  • memory CD4 T-cell: 3 nTPM
  • memory B-cell: 2.7 nTPM
  • naive CD4 T-cell: 2.7 nTPM

Brain region

  • white matter: 59 nTPM
  • cerebellum: 58 nTPM
  • medulla oblongata: 54 nTPM
  • pons: 52 nTPM
  • choroid plexus: 50 nTPM
  • hypothalamus: 49 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about HNRNPA2B1.

Disease | AllUniProt

Conditions HNRNPA2B1 is implicated in, by any mechanism.

  • Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2 (IBMPFD2) MIM:615422
  • Oculopharyngeal muscular dystrophy 2 (OPMD2) MIM:620460

Disease | GeneticClinVar

6 pathogenic / likely-pathogenic of 427 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Oculopharyngeal muscular dystrophy 2
  • Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2
  • Frontotemporal dementia

Disease | ImmuneIEDB

Conditions an epitope on HNRNPA2B1 was assayed in.

ReferencesPubMed · IEDB

Publications for HNRNPA2B1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

3 publications

Reference: B cellIEDB

4 publications

Reference: T cellIEDB

3 publications

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.22
gnomAD pLI
1
gnomAD missense Z
3
DepMap mean gene effect
-0.32
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of HNRNPA2B1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads HNRNPA2B1 as an antibody target. Whether an autoantibody or antibody against HNRNPA2B1 could matter depends on whether native HNRNPA2B1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

HNRNPA2B1 is annotated as secreted, so native HNRNPA2B1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label HNRNPA2B1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/HNRNPA2B1. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...